During development, 17 alpha-estradiol is a potent estrogen and carcinogen

被引:17
作者
Hajek, RA
Robertson, AD
Johnston, DA
Van, NT
Tcholakian, RK
Wagner, LA
Conti, CJ
Meistrich, ML
Contreras, N
Edwards, CL
Jones, LA
机构
[1] UNIV TEXAS,MD ANDERSON CANC CTR,DEPT GYNECOL ONCOL,EXPT GYNECOL ENDOCRINOL LAB,HOUSTON,TX 77030
[2] UNIV TEXAS,MD ANDERSON CANC CTR,DEPT HEMATOL,HOUSTON,TX 77030
[3] UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BIOMATH,HOUSTON,TX 77030
[4] UNIV TEXAS,MD ANDERSON CANC CTR,DEPT CARCINOGENESIS,HOUSTON,TX 77030
[5] UNIV TEXAS,MD ANDERSON CANC CTR,DEPT EXPT RADIOTHERAPY,HOUSTON,TX 77030
[6] UNIV TEXAS,HLTH SCI CTR,DEPT OB GYN REPROD SCI & PLANNING,HOUSTON,TX
[7] UNIV CTR VENEZUELA,DEPT MORF,CARACAS,VENEZUELA
关键词
carcinogen; cervicovaginal; endocrine disruptor; estradiol; estrogen; development; neonatal; mouse;
D O I
10.2307/3433373
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
Neonatal administration of estradiol-17 beta (E-2-17 beta) increases the nuclear DNA content in the mouse reproductive tract. Similar responses have been demonstrated for synthetic estrogens such as diethylstilbestrol. One of the questions raised regarding environmental estrogens such as organochlorines is whether they are potent enough to result in abnormal changes such as those demonstrated by both natural and synthetic estrogens. To test this hypothesis, female BALB/c mice were treated neonatally (days 1-5) with either E-2-17 beta or estradiol-17 alpha (E-2-17 alpha), an inactive stereoisomer in adult reproductive tissues. We also proposed whether neonatal administration of (E-2-17 alpha) was tumorigenic and whether the effects were age dependent. To answer these questions, one set each of 10-day-old treated and control mice received short-term secondary administration of E-2-17 beta, E-2-17 alpha, or cholesterol. Cervicovaginal tracts from intact BALB/c mice were examined histologically and by flow cytometry at 70 days of age and by histology alone at 18 to 22 months of age. The results include several important findings: a) like E-2-17 beta, neonatal E-2-17 alpha treatment induced persistent vaginal cornification, hypospadias, vaginal concreticns, and hyperproliferation in nearly 100% of the animals regardless of the secondary treatment for most groups; b) neonatal E-2-17 alpha treatment increased the nuclear DNA content of cervicovaginal epithelium at one-half both the level (mean DNA index of 1.02 vs 1.04) and incidence (22 vs 46% of the animals) of E-2-17 beta; c) short-term secondary treatment with E-2-17 alpha, unlike E-2-17 beta, did not significantly augment the increase in DNA content (13% for E-2-17 alpha vs 37 and 56% for control and E-2-17 beta, respectively); and d) neonatal administration with E-2-17 alpha induced adenosquamous tumors in the reproductive tract in 25% of the animals. Therefore, the biological effects (estrogenic potency) of E-2-17 alpha may be age dependent.
引用
收藏
页码:577 / 581
页数:5
相关论文
共 33 条
[1]   REGULATION OF PROLACTIN PRODUCTION AND CELL-GROWTH BY ESTRADIOL - DIFFERENCE IN SENSITIVITY TO ESTRADIOL OCCURS AT LEVEL OF MESSENGER-RIBONUCLEIC-ACID ACCUMULATION [J].
AMARA, JF ;
VANITALLIE, C ;
DANNIES, PS .
ENDOCRINOLOGY, 1987, 120 (01) :264-271
[2]  
BARRETT JC, 1985, MECH CARCINOGENESIS, P123
[3]   THE DEVELOPMENT OF THE ROLE OF HORMONES IN DEVELOPMENT - A DOUBLE REMEMBRANCE [J].
BERN, HA .
ENDOCRINOLOGY, 1992, 131 (05) :2037-2038
[4]  
BERN HA, 1992, HORMONAL CARCINOGENESIS, P1
[5]   INTERACTION OF RING-B UNSATURATED ESTROGENS WITH ESTROGEN-RECEPTORS OF HUMAN ENDOMETRIUM AND RAT UTERUS [J].
BHAVNANI, BR ;
WOOLEVER, CA .
STEROIDS, 1991, 56 (04) :201-210
[6]   STRAIN DIFFERENCES IN THE ONTOGENY OF ESTROGEN-RECEPTORS IN MURINE UTERINE EPITHELIUM [J].
BIGSBY, RM ;
AIXIN, L ;
LUO, K ;
CUNHA, GR .
ENDOCRINOLOGY, 1990, 126 (05) :2592-2596
[7]   EFFECTS OF ESTRADIOL-17-ALPHA ON NUCLEAR OCCUPANCY OF THE ESTROGEN-RECEPTOR, STIMULATION OF NUCLEAR TYPE-II SITES AND UTERINE GROWTH [J].
CLARK, JH ;
WILLIAMS, M ;
UPCHURCH, S ;
ERIKSSON, H ;
HELTON, E ;
MARKAVERICH, BM .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1982, 16 (02) :323-328
[8]   HORMONAL ASPECTS OF BREAST-CANCER - GROWTH-FACTORS, DRUGS AND STROMAL INTERACTIONS [J].
CLARKE, R ;
DICKSON, RB ;
LIPPMAN, ME .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 1992, 12 (01) :1-23
[9]  
Colborn T., 1992, CHEM INDUCED ALTERAT
[10]  
DAVIS DL, 1995, SCI AM, V273, P166